secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2025-04-24T23:59:59+00:00
Accession:  0000105770-25-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Q1 sales $698M (+0.4%), adj. EPS $1.45; raises FY2025 net sales and adj. EPS guidance
--------------------------------------------------------------------------------

- Net sales $698.0M (+0.4% reported, +2.1% organic); reported EPS $1.23 vs $1.55 YoY; adj. EPS $1.45 vs $1.56 YoY.
- Full-year 2025 net sales guidance raised to $2.945B-$2.975B (prior $2.875B-$2.905B); adj. EPS guidance raised to $6.15-$6.35 (prior $6.00-$6.20).
- Q3 2025 dividend declared at $0.21/share, payable Aug 6, 2025 to holders of record July 30, 2025.
- Free cash flow $58.1M (up from $27.6M YoY); repurchased 550,281 shares for $133.5M in Q1.
- Guidance includes $20-25M net impact from tariffs; organic net sales growth expected ~2%-3% for FY2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577025000029/0000105770-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577025000029/wst-20250424.htm
  HTML page:      https://secwatch.observer/filing/0000105770-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer